Theravance Biopharma, Inc. (NASDAQ:TBPH) Receives Average Rating of “Hold” from Analysts

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) have received a consensus rating of “Hold” from the five analysts that are currently covering the firm, Marketbeat reports. Three research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $13.75.

Separately, HC Wainwright restated a “buy” rating and issued a $15.00 price objective on shares of Theravance Biopharma in a research note on Tuesday, February 25th.

Theravance Biopharma Stock Down 2.1 %

NASDAQ:TBPH opened at $9.15 on Tuesday. The stock’s 50 day moving average price is $9.32 and its two-hundred day moving average price is $8.94. The firm has a market capitalization of $449.94 million, a price-to-earnings ratio of -9.06 and a beta of 0.21. Theravance Biopharma has a 12-month low of $7.44 and a 12-month high of $10.90.

Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings data on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.26). The business had revenue of $18.75 million during the quarter, compared to the consensus estimate of $29.90 million. Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. Equities research analysts expect that Theravance Biopharma will post -1.09 EPS for the current year.

Insider Transactions at Theravance Biopharma

In related news, SVP Rhonda Farnum sold 4,000 shares of the stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $9.00, for a total transaction of $36,000.00. Following the sale, the senior vice president now owns 309,565 shares of the company’s stock, valued at $2,786,085. This represents a 1.28 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 6.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Theravance Biopharma

Large investors have recently added to or reduced their stakes in the stock. Barclays PLC grew its position in Theravance Biopharma by 279.9% during the third quarter. Barclays PLC now owns 65,580 shares of the biopharmaceutical company’s stock worth $529,000 after buying an additional 48,316 shares in the last quarter. JPMorgan Chase & Co. grew its position in Theravance Biopharma by 2.9% during the third quarter. JPMorgan Chase & Co. now owns 266,879 shares of the biopharmaceutical company’s stock worth $2,151,000 after buying an additional 7,620 shares in the last quarter. Algert Global LLC acquired a new stake in Theravance Biopharma during the third quarter worth approximately $851,000. Jane Street Group LLC grew its position in Theravance Biopharma by 1.1% during the third quarter. Jane Street Group LLC now owns 144,575 shares of the biopharmaceutical company’s stock worth $1,165,000 after buying an additional 1,640 shares in the last quarter. Finally, BNP Paribas Financial Markets boosted its holdings in shares of Theravance Biopharma by 88.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 305,480 shares of the biopharmaceutical company’s stock valued at $2,462,000 after purchasing an additional 143,781 shares in the last quarter. Institutional investors and hedge funds own 99.10% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.